Healthcare Equipment and Supplies
Company Overview of BIOTRONIK SE & Co. KG
BIOTRONIK SE & Co. KG designs, develops, manufactures, and sells implantable cardiac devices in Germany and internationally. The company offers devices and therapy solutions for various phases of patient care ranging from diagnosis and treatment to patient management. It also provides cardioverter-defibrillators/cardiac resynchronization therapy defibrillators for magnetic resonance imaging. The company offers its therapy solutions for cardiac rhythm or cardiovascular diseases. It serves physicians, hospitals, and patients. The company was founded in 1963 and is headquartered in Berlin, Germany. It has research and development, and production sites in Germany, Switzerland, and the United Sta...
Founded in 1963
Key Executives for BIOTRONIK SE & Co. KG
Managing Director and Member of Executive Board
Chief Executive Officer of Vascular Intervention
Senior Director of Corporate Communications
Director of Marketing for Vascular Intervention
Compensation as of Fiscal Year 2013.
BIOTRONIK SE & Co. KG Key Developments
BIOTRONIK Announces European Market Launch of its Ilesto 7 Series
Jun 20 13
BIOTRONIK announced the European market launch of its Ilesto 7 Series. Ilesto 7 is the DF4 ICD/CRT series approved for MRI, and includes ICDs while also offering the longevity -- up to 11.5 years for the single chamber ICD.
BIOTRONIK SE & Co. KG Announces Completion of Enrollment in Impact Study to Investigate Stroke Risk Reduction in Patients with Atrial Fibrillation
May 23 13
BIOTRONIK SE & Co. KG announced that enrollment has been completed for the highly anticipated IMPACT study. The study aims to investigate whether the use of BIOTRONIK Home Monitoring(R) in conjunction with anticoagulation can reduce the risks of stroke, systemic embolism and major bleeding in cardiac device patients. 2,718 patients at 100 clinical sites in the US, Canada, Germany, Australia, the UK, and Denmark have been enrolled in this randomized, international, multi-center trial. Participants in the study have been implanted with a BIOTRONIK Lumax DR-T/HF-T device with BIOTRONIK Home Monitoring(R). IMPACT will compare patient outcomes between two randomized groups. The first group is being continuously monitored for symptomatic or asymptomatic atrial fibrillation using BIOTRONIK Home Monitoring(R), and subsequently treated using a pre-defined anticoagulation plan. The second group is receiving conventional device evaluation at in-office follow up visits for detection of atrial fibrillation events and physician-directed anticoagulation based on the patient's medical history. The study design was published in the American Heart Journal, September 2009. BIOTRONIK Home Monitoring(R) rapidly detects anomalies in patients' cardiac health, continuously transmits data on a daily basis and notifies medical staff with appropriate alerts without the need for any patient interaction. The early detection of clinically relevant events, including the duration of atrial fibrillation and the advantageous detection of asymptomatic events, enables the physician to adapt patient therapy at a very early stage.
BIOTRONIK SE & Co. KG Receives FDA Approval for llesto 7 ICD/CRT-D Series
May 7 13
BIOTRONIK SE & Co. KG announced that the Food and Drug Administration (FDA) granted approval for its Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator (ICD/CRT-D) series. The Ilesto devices exemplify the principled engineering for which BIOTRONIK is known. The devices are smaller, thinner and lighter without compromising clinical capabilities. The Ilesto 7 series is now approved and currently available in most international markets, including the EU and Japan. In C.E. markets, the Ilesto 7 series is the second generation of BIOTRONIK's ProMRI(R) technology, which enables patients access to potentially life-saving MR scans.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|